AMGN vs. BIB

Last updated Apr 1, 2026

Compare and contrast key facts about Amgen Inc. (AMGN) and ProShares Ultra Nasdaq Biotechnology (BIB).

BIB is a passively managed fund by ProShares that tracks the performance of the NASDAQ Biotechnology Index (200%). It was launched on Apr 7, 2010.

Performance

AMGN vs. BIB - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Amgen Inc. (AMGN) and ProShares Ultra Nasdaq Biotechnology (BIB). The values are adjusted to include any dividend payments, if applicable.

AMGN vs. BIB - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
AMGN Amgen Inc.	8.24%	29.67%	-6.77%	13.46%	20.43%	0.87%	-1.99%	27.60%	15.23%	22.27%
BIB ProShares Ultra Nasdaq Biotechnology	2.18%	59.21%	-9.84%	-1.06%	-28.85%	-6.02%	39.79%	46.71%	-24.93%	40.49%

Returns By Period

In the year-to-date period, AMGN achieves a 8.24% return, which is significantly higher than BIB's 2.18% return. Over the past 10 years, AMGN has outperformed BIB with an annualized return of 11.88%, while BIB has yielded a comparatively lower 6.84% annualized return.

AMGN

• 1D: 0.82%
• 1M: -9.35%
• YTD: 8.24%
• 6M: 26.44%
• 1Y: 16.48%
• 3Y*: 16.93%
• 5Y*: 10.56%
• 10Y*: 11.88%

BIB

• 1D: 9.12%
• 1M: -7.53%
• YTD: 2.18%
• 6M: 37.07%
• 1Y: 70.62%
• 3Y*: 15.61%
• 5Y*: -0.24%
• 10Y*: 6.84%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

AMGN vs. BIB — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

AMGN

AMGN Risk / Return Rank: 62
AMGN Sharpe Ratio Rank: 63
AMGN Sortino Ratio Rank: 57
AMGN Omega Ratio Rank: 55
AMGN Calmar Ratio Rank: 67
AMGN Martin Ratio Rank: 67

BIB

BIB Risk / Return Rank: 81
BIB Sharpe Ratio Rank: 80
BIB Sortino Ratio Rank: 80
BIB Omega Ratio Rank: 71
BIB Calmar Ratio Rank: 88
BIB Martin Ratio Rank: 85

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

AMGN vs. BIB - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Amgen Inc. (AMGN) and ProShares Ultra Nasdaq Biotechnology (BIB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	AMGN	BIB	Difference
Sharpe ratio Return per unit of total volatility	0.57	1.50	-0.93
Sortino ratio Return per unit of downside risk	1.03	2.04	-1.01
Omega ratio Gain probability vs. loss probability	1.13	1.26	-0.13
Calmar ratio Return relative to maximum drawdown	1.15	2.76	-1.61
Martin ratio Return relative to average drawdown	2.80	9.82	-7.02
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

AMGN vs. BIB - Sharpe Ratio Comparison

The current AMGN Sharpe Ratio is 0.57, which is lower than the BIB Sharpe Ratio of 1.50. The chart below compares the historical Sharpe Ratios of AMGN and BIB, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	AMGN	BIB	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.57	1.50	-0.93
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.44	-0.01	+0.45
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.48	0.15	+0.34
Sharpe Ratio (All Time) Calculated using the full available price history	0.61	0.34	+0.27

Correlation

The correlation between AMGN and BIB is 0.65, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Dividends

AMGN vs. BIB - Dividend Comparison

AMGN's dividend yield for the trailing twelve months is around 2.75%, more than BIB's 0.60% yield.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
AMGN Amgen Inc.	2.75%	2.91%	3.45%	2.96%	2.95%	3.13%	2.78%	2.41%	2.71%	2.65%	2.74%	1.95%
BIB ProShares Ultra Nasdaq Biotechnology	0.60%	0.77%	1.69%	0.07%	0.03%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Drawdowns

AMGN vs. BIB - Drawdown Comparison

The maximum AMGN drawdown since its inception was -63.48%, smaller than the maximum BIB drawdown of -67.24%. Use the drawdown chart below to compare losses from any high point for AMGN and BIB.

Drawdown Indicators

	AMGN	BIB	Difference
Max Drawdown Largest peak-to-trough decline	-63.48%	-67.24%	+3.76%
Max Drawdown (1Y) Largest decline over 1 year	-15.35%	-21.73%	+6.38%
Max Drawdown (5Y) Largest decline over 5 years	-24.86%	-65.86%	+41.00%
Max Drawdown (10Y) Largest decline over 10 years	-24.86%	-66.20%	+41.34%
Current Drawdown Current decline from peak	-9.35%	-24.88%	+15.53%
Average Drawdown Average peak-to-trough decline	-16.80%	-32.85%	+16.05%
Ulcer Index Depth and duration of drawdowns from previous peaks	6.51%	6.52%	-0.01%

Volatility

AMGN vs. BIB - Volatility Comparison

The current volatility for Amgen Inc. (AMGN) is 6.34%, while ProShares Ultra Nasdaq Biotechnology (BIB) has a volatility of 17.28%. This indicates that AMGN experiences smaller price fluctuations and is considered to be less risky than BIB based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	AMGN	BIB	Difference
Volatility (1M) Calculated over the trailing 1-month period	6.34%	17.28%	-10.94%
Volatility (6M) Calculated over the trailing 6-month period	20.60%	28.86%	-8.26%
Volatility (1Y) Calculated over the trailing 1-year period	29.02%	47.37%	-18.35%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	23.87%	43.32%	-19.45%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	24.74%	46.78%	-22.04%